Physician profile
Donald E Aspenson
NPI 1225008550
$153,303.32
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $26K · 2021: $8,287 · 2022: $14K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54,944.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36,936.32 | 2019-2021 | |
| Amgen INC. | $24,128.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,408.54 | 2019-2022 | |
| Lilly USA, LLC | $13,746.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $5,693.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,488.10 | 2019-2021 | |
| Abbott Laboratories | $220.58 | 2019-2022 | |
| Antares Pharma, INC. | $85.93 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $77.55 | 2019 | |
| Currax Pharmaceuticals LLC | $72.02 | 2019-2022 | |
| Medtronic, INC. | $52.46 | 2022 | |
| Endo Pharmaceuticals INC. | $46.60 | 2019-2022 | |
| Corcept Therapeutics | $34.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.39 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.14 | 2019 | |
| Abbvie INC. | $27.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.33 | 2019-2021 | |
| Sandoz INC. | $26.06 | 2019-2020 | |
| Dexcom, INC. | $25.74 | 2021-2022 | |
| Gilead Sciences, INC. | $25.16 | 2019 | |
| Tandem Diabetes Care, INC. | $23.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.43 | 2019-2020 | |
| Valeritas, INC. | $21.82 | 2019 | |
| Mannkind Corporation | $20.75 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $17.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.80 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $13.79 | 2019 | |
| Aytu Biopharma, INC. | $13.35 | 2019 | |
| Vistapharm, INC. | $11.80 | 2021 | |
| Siemens Medical Solutions USA, INC. | $11.57 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Aspenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.